REGENXBIO Inc. (RGNX) Investor Relations Documents

REGENXBIO Inc. (RGNX) investor relations documents from the company's IR site: 1 presentation, 20 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Corporate Presentation: REGENXBIO is a gene therapy company advancing a pipeline of rare and retinal disease treatments, led by the pivotal success of RGX-202 for Duchenne Muscular Dystrophy.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseREGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-05PresentationCorporate Presentation
2026-08-03Press releaseREGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlight
2026-07-18Press releaseREGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Soc
2026-07-17Press releaseREGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
2026-07-16Press releaseREGENXBIO Announces Proposed Public Offering of Common Stock
2026-06-29Press releaseREGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopath
2026-06-24Press releaseREGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program an
2026-06-22Press releaseREGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Po
2026-05-18Press releaseREGENXBIO to Participate in Upcoming Investor Conferences
2026-05-14Press releaseREGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
2026-05-14Press releaseREGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
2026-05-06Press releaseREGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystr
2026-03-05Press releaseREGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
2026-03-04Press releaseREGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2026-03-02Press releaseREGENXBIO to Participate in Upcoming Investor Conferences
2026-02-25Press releaseREGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operatio
2026-02-09Press releaseREGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
2026-01-28Press releaseREGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
2026-01-11Press releaseREGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Thera
Press releaseREGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent

RGNX overview · RGNX earnings · RGNX financials · RGNX KPIs · RGNX ownership · RGNX peers · RGNX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.